CG0009

CG0009 is a potent, selective GSK3 inhibitor that suppresses proliferation and triggers apoptosis in breast cancer cells via cyclin D1 depletion and p53-Bax pathway activation. This mechanism supports its investigation as a potential therapeutic strategy, particularly in hormone therapy-resistant breast cancer models, in both in vitro and in vivo research settings.